Format

Send to

Choose Destination
BMJ. 2018 May 9;361:k1551. doi: 10.1136/bmj.k1551.

Vertebroplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): randomised sham controlled clinical trial.

Author information

1
Departments of Radiology and Internal Medicine, Elisabeth TweeSteden Hospital, Hilvarenbeekseweg 60, 5022 GC, Tilburg, Netherlands crisfiranescu@hotmail.com.
2
Departments of Radiology and Internal Medicine, Elisabeth TweeSteden Hospital, Hilvarenbeekseweg 60, 5022 GC, Tilburg, Netherlands.
3
Department of Medical and Clinical Psychology, Tilburg University, Tilburg, Netherlands.
4
Department of Radiology, Medisch Spectrum Twente, Enschede, Netherlands.
5
Department of Radiology, Albert Schweitzer Hospital, Dordrecht, Netherlands.
6
Department of Radiology, Catharina Hospital, Eindhoven, Netherlands.
7
Department of Radiology, Massachusetts General Hospital, MA, Boston, USA.

Abstract

OBJECTIVE:

To assess whether percutaneous vertebroplasty results in more pain relief than a sham procedure in patients with acute osteoporotic compression fractures of the vertebral body.

DESIGN:

Randomised, double blind, sham controlled clinical trial.

SETTING:

Four community hospitals in the Netherlands, 2011-15.

PARTICIPANTS:

180 participants requiring treatment for acute osteoporotic vertebral compression fractures were randomised to either vertebroplasty (n=91) or a sham procedure (n=89).

INTERVENTIONS:

Participants received local subcutaneous lidocaine (lignocaine) and bupivacaine at each pedicle. The vertebroplasty group also received cementation, which was simulated in the sham procedure group.

MAIN OUTCOME MEASURES:

Main outcome measure was mean reduction in visual analogue scale (VAS) scores at one day, one week, and one, three, six, and 12 months. Clinically significant pain relief was defined as a decrease of 1.5 points in VAS scores from baseline. Secondary outcome measures were the differences between groups for changes in the quality of life for osteoporosis and Roland-Morris disability questionnaire scores during 12 months' follow-up.

RESULTS:

The mean reduction in VAS score was statistically significant in the vertebroplasty and sham procedure groups at all follow-up points after the procedure compared with baseline. The mean difference in VAS scores between groups was 0.20 (95% confidence interval -0.53 to 0.94) at baseline, -0.43 (-1.17 to 0.31) at one day, -0.11 (-0.85 to 0.63) at one week, 0.41 (-0.33 to 1.15) at one month, 0.21 (-0.54 to 0.96) at three months, 0.39 (-0.37 to 1.15) at six months, and 0.45 (-0.37 to 1.24) at 12 months. These changes in VAS scores did not, however, differ statistically significantly between the groups during 12 months' follow-up. The results for secondary outcomes were not statistically significant. Use of analgesics (non-opioids, weak opioids, strong opioids) decreased statistically significantly in both groups at all time points, with no statistically significant differences between groups. Two adverse events occurred in the vertebroplasty group: one respiratory insufficiency and one vasovagal reaction.

CONCLUSIONS:

Percutaneous vertebroplasty did not result in statistically significantly greater pain relief than a sham procedure during 12 months' follow-up among patients with acute osteoporotic vertebral compression fractures.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01200277.

PMID:
29743284
PMCID:
PMC5941218
DOI:
10.1136/bmj.k1551
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. JAH has received consulting fees from Medtronic and Globus as well as serving on a data and safety monitoring board of a study sponsored by Codman Neurovascular.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center